Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Over for now..?

<< Previous

Bullboard Posts

Next >>

Post by Nicksonsnowboaron Aug 10, 2021 10:50am

534 Views

Post# 33677982

Over for now..?

lt had its 15 minutes of fame just before being listed on the nas. Looks like it just dead money ,nothing going to occur for over a year . increasing cost with no given promising outcomes will probably keep in the low $2 if not lower going forward . Hype i do not think is going to substain it. Thoughts?

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale